JP Morgan Chase’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,414,770
| Closed | -$151M | – | 7809 |
|
|
2025
Q3 | $151M | Buy |
1,414,770
+1,058,163
| +297% | +$110M | 0.01% | 816 |
|
|
2025
Q2 | $33.7M | Buy |
356,607
+345,012
| +2,976% | +$25.5M | ﹤0.01% | 1595 |
|
|
2025
Q1 | $736K | Sell |
11,595
-1,268
| -10% | -$75.8K | ﹤0.01% | 4545 |
|
|
2024
Q4 | $597K | Sell |
12,863
-1,197
| -9% | -$44.9K | ﹤0.01% | 4944 |
|
|
2024
Q3 | $405K | Buy |
14,060
+3,696
| +36% | +$91K | ﹤0.01% | 5044 |
|
|
2024
Q2 | $150K | Sell |
10,364
-7,277
| -41% | -$106K | ﹤0.01% | 5307 |
|
|
2024
Q1 | $284K | Buy |
17,641
+4,882
| +38% | +$84.4K | ﹤0.01% | 5140 |
|
|
2023
Q4 | $254K | Buy |
12,759
+47
| +0.4% | +$694 | ﹤0.01% | 5239 |
|
|
2023
Q3 | $207K | Buy |
12,712
+9,559
| +303% | +$184K | ﹤0.01% | 5051 |
|
|
2023
Q2 | $66.7K | Sell |
3,153
-214,417
| -99% | -$4.57M | ﹤0.01% | 5636 |
|
|
2023
Q1 | $4.37M | Buy |
217,570
+215,639
| +11,167% | +$4.66M | ﹤0.01% | 2941 |
|
|
2022
Q4 | $50K | Sell |
1,931
-61,348
| -97% | -$817K | ﹤0.01% | 5626 |
|
|
2022
Q3 | $647K | Buy |
+63,279
| New | +$533K | ﹤0.01% | 4291 |
|
|
2021
Q2 | – | Sell |
-35
| Closed | – | – | 6636 |
|
|
2021
Q1 | $0 | Sell |
35
-348
| -91% | -$2.89K | ﹤0.01% | 6381 |
|
|
2020
Q4 | $3K | Buy |
+383
| New | +$2.59K | ﹤0.01% | 5496 |
|
Other funds holding VRNA
JP Morgan Chase's VRNA Position: Q4 2025 in Review
JP Morgan Chase sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 1,414,770 shares — an estimated $151M sold.
JP Morgan Chase first reported a position in VRNA in Q4 2020 and held it in 15 quarters. The position peaked at $151M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- JP Morgan Chase reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- JP Morgan Chase sold 1,414,770 Verona Pharma shares in Q4 2025, an estimated $151M.
- JP Morgan Chase first reported a position in Verona Pharma in Q4 2020 and held it in 15 quarters.
- JP Morgan Chase's Verona Pharma position peaked at $151M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.